MedPath

Moderate to severe fatigue in patients with interstitial lung disease (FAntasTIGUE-ILD)

Conditions
Fatigue, ILD, IPF, Sarcoidosis
Registration Number
NL-OMON21789
Lead Sponsor
O
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

Clinically stable diagnosed pulmonary fibrosis or sarcoidosis (no exacerbation/hospitalization <4 weeks) from the outpatient clinic of the Department of Respiratory Medicine (Zuyderland Heerlen or Sittard)

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

1.Lack of sufficient understanding of the Dutch language;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fatigue, measured by the Cis-Fat (Attachment A), is the primary outcome. The Cis-Fat consists of eight items, scored on a 7-point Likert scale. The range of scores is from 8 (normal fatigue) to 56 (most severe fatigue), with a higher score indicating a higher level of fatigue. Scores ¡Ü26 points indicate normal fatigue, scores 27 to 35 indicate moderate fatigue and scores ¡Ý35 indicate severe fatigue
Secondary Outcome Measures
NameTimeMethod
Demographic data (as age, gender, lungfunction, medication, etc) and questionnaires (as mMRC, VAS, CAT, EQ-5D-5L, HADS, ADIQ, KWAMOE, FCS, PAM)
© Copyright 2025. All Rights Reserved by MedPath